Country for PR: United Kingdom
Contributor: PR Newswire Europe
Monday, July 05 2021 - 10:00
Insightec Announces Registration Approval Of Exablate Neuro By Singapore Health Sciences Authority
HAIFA, Israel and MIAMI, July 5, 2021 /PRNewswire-AsiaNet/ --

Positive momentum continues to bring Focused Ultrasound to global patients 
living with Essential Tremor and Tremor-dominant Parkinson's Disease

Insightec(R) [ ], a global healthcare company focused 
on creating the next generation of patient care, announced approval of the 
Exablate(R) Neuro platform by the Health Sciences Authority (HSA) in Singapore. 

The Exablate Neuro (Exablate 4000) platform uses Focused Ultrasound to ablate a 
target deep in the brain. The unilateral treatment is suitable for patients 
with Essential Tremor (age 22 or older) or Tremor-dominant Parkinson's Disease 
(age 30 or older) who have not responded to medications. 

"The value of Focused Ultrasound for medical centers treating movement 
disorders is greatly improved patient care," said Maurice R. Ferré MD, 
Insightec CEO and Chairman of the Board of Directors. "Our technology enables 
patients to go from a life dominated by tremor to the potential for a calm, 
steady hand."

There are 81 leading medical centers globally that have established Focused 
Ultrasound programs with Exablate Neuro. Insightec is working with Transmedic [ ]Group, a leading distributor of advanced 
medical technology in Southeast Asia, to advance adoption of the Exablate Neuro 
in the Singapore market.  

"We are excited to bring this transformational technology to medical centers in 
Singapore," commented Teo Kee Meng, Transmedic Managing Director.  "More 
importantly, patients will now have the option to choose a treatment that is 
outpatient and incisionless."

About Insightec
Insightec is a global healthcare company creating the next generation of 
patient care by realizing the therapeutic power of acoustic energy. The 
company's Exablate(R) Neuro platform focuses sound waves, safely guided by MRI, 
to provide tremor treatment to patients with Essential Tremor and 
Tremor-dominant Parkinson's Disease. Research for future applications in the 
neuroscience space is underway in partnership with leading academic and medical 
institutions. Insightec is headquartered in Haifa, Israel, and Miami, with 
offices in Dallas, Shanghai and Tokyo.

Follow us on  Facebook [ ], LinkedIn 
[ ]and Twitter [ ]or visit for more information.

Forward-looking Statements
This document contains forward-looking statements regarding, among other 
things, plans, expectations, and future events.  In some cases, forward-looking 
statements can be identified by the following words: "may," "can," "will," 
"could," "would," "should," "expect," "intend," "plan," "anticipate," 
"believe," "estimate," "predict," "project," "potential," "promise," 
"continue," "ongoing," or the negative of these terms. Forward-looking 
statements involve known and unknown risks, uncertainties and other important 
factors that could cause actual results to differ materially from what is 
expressed or implied by the statements. Any forward-looking statement is based 
on information available to Insightec as of the date of the statement. All 
written or oral forward-looking statements attributable to Insightec are 
qualified by this caution. Insightec does not undertake any obligation to 
update or revise any forward-looking statement to reflect any change in 
circumstances or in Insightec's expectations.

"Exablate," and "Exablate Neuro," as well as the "INSIGHTEC" logo, whether 
standing alone or in connection with the word " Insightec", are protected 
trademarks of Insightec.

Insightec Media Contact
G&S Business Communications for Insightec
Elizabeth Mannheimer
+1 917.595.3034 

Logo -

Source: Insightec